ADA and Endocrinology Organizations Release Statement On Avandia
The diabetes medication rosiglitazone (Avandia) continues to draw fire, most recently in reports from the Food and Drug Administration (FDA), which is currently investigating the drug for cardiovascular safety, and the New York Times. In light of these concerns, the American Diabetes Association, The Endocrine Society, and the American Association of Clinical Endocrinologists released today a joint statement.
According to the three organizations, people with type 2 diabetes should continue taking all prescribed medications, since stopping the drugs can lead to high blood glucose levels. But the statement also reminds people taking rosiglitazone that there are various other oral medications available to treat diabetes. Anyone concerned about its safety should speak with their doctor about other options.
The FDA is expected to rule on the drug's safety—and whether or not Avandia should remain on the market—within a few days.